ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
July 13, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced plans to design a...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
July 06, 2023 08:29 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...
71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
June 28, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), announced the results of a...
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
June 08, 2023 16:08 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of...
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
May 30, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the...
ProSomnus Reports First Quarter 2023 Financial Results
May 09, 2023 16:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea...
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
April 26, 2023 09:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), will...
Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
April 24, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting
April 18, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...
ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
April 05, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today...